IGC Pharma, Inc.
IGC · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $37,712 | $25,406 | $21,807 | $26,085 |
| - Cash | $1,105 | $454 | $405 | $470 |
| + Debt | $137 | $202 | $238 | $397 |
| Enterprise Value | $36,744 | $25,154 | $21,640 | $26,012 |
| Revenue | $191 | $328 | $330 | $257 |
| % Growth | -41.8% | -0.6% | 28.4% | – |
| Gross Profit | $99 | $154 | $154 | $104 |
| % Margin | 51.8% | 47% | 46.7% | 40.5% |
| EBITDA | -$1,702 | -$1,764 | -$1,258 | -$1,721 |
| % Margin | -891.1% | -537.8% | -381.2% | -669.6% |
| Net Income | -$1,821 | -$1,599 | -$1,197 | -$1,829 |
| % Margin | -953.4% | -487.5% | -362.7% | -711.7% |
| EPS Diluted | -0.02 | -0.019 | -0.016 | -0.024 |
| % Growth | -3.6% | -23.7% | 33.9% | – |
| Operating Cash Flow | -$2,090 | -$1,407 | -$730 | -$1,317 |
| Capital Expenditures | -$29 | -$122 | -$166 | -$27 |
| Free Cash Flow | -$2,119 | -$1,529 | -$896 | -$1,344 |